Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Glucocorticoid-induced osteoporosis and osteonecrosis.

Literature DB >> 22877431

Glucocorticoid-induced osteoporosis and osteonecrosis.

Abstract

Glucocorticoid administration is the most common cause of secondary osteoporosis and the leading cause of nontraumatic osteonecrosis. In patients receiving long-term therapy, glucocorticoids induce fractures in 30% to 50% and osteonecrosis in 9% to 40%. This article reviews glucocorticoid-induced osteoporosis and osteonecrosis, addressing the risk factors, pathogenesis, evaluation, treatment, and uncertainties in the clinical management of these disorders. Published by Elsevier Inc.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22877431 PMCID： PMC3417039 DOI： 10.1016/j.ecl.2012.04.004

Source DB: PubMed Journal: Endocrinol Metab Clin North Am ISSN： 0889-8529 Impact factor: 4.741

60 in total

1. Management of rheumatoid arthritis with smaller (maintenance) doses of cortisone acetate.

Authors: E W BOLAND; N E HEADLEY
Journal: J Am Med Assoc Date: 1950-09-30

2. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.

Authors: Kuo-An Lai; Wun-Jer Shen; Chyun-Yu Yang; Chung-Jung Shao; Jui-Ting Hsu; Ruey-Mo Lin
Journal: J Bone Joint Surg Am Date: 2005-10 Impact factor: 5.284

Review 3. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors: Karen E Hansen; H Alexander Wilson; Carol Zapalowski; Howard A Fink; Salvatore Minisola; Robert A Adler
Journal: J Bone Miner Res Date: 2011-06-30 Impact factor: 6.741

4. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.

Authors: Ronald Emkey; Pierre D Delmas; Stefan Goemaere; Uri A Liberman; Patrice E Poubelle; Anastasia G Daifotis; Nadia Verbruggen; Antonio Lombardi; Michelle Czachur
Journal: Arthritis Rheum Date: 2003-04

5. Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density.

Authors: J M Thompson; G W Modin; C D Arnaud; N E Lane
Journal: Calcif Tissue Int Date: 1997-11 Impact factor: 4.333

6. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip.

Authors: R S Weinstein; R W Nicholas; S C Manolagas
Journal: J Clin Endocrinol Metab Date: 2000-08 Impact factor: 5.958

7. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors: Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal: J Bone Miner Res Date: 2007-10 Impact factor: 6.741

8. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.

Authors: Robin K Dore; Stanley B Cohen; Nancy E Lane; William Palmer; William Shergy; Lifen Zhou; Huei Wang; Wayne Tsuji; Richard Newmark
Journal: Ann Rheum Dis Date: 2009-09-03 Impact factor: 19.103

9. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice.

Authors: Robert S Weinstein; Chao Wan; Qinglan Liu; Ying Wang; Maria Almeida; Charles A O'Brien; Jeff Thostenson; Paula K Roberson; Adele L Boskey; Thomas L Clemens; Stavros C Manolagas
Journal: Aging Cell Date: 2009-12-28 Impact factor: 9.304

10. Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases.

Authors: Ichiro Tatsuno; Takao Sugiyama; Sawako Suzuki; Tomohiko Yoshida; Tomoaki Tanaka; Makoto Sueishi; Yasushi Saito
Journal: J Clin Endocrinol Metab Date: 2009-03-03 Impact factor: 5.958

111 in total

Review 1. The Key Role of the Blood Supply to Bone.

Authors: Massimo Marenzana; Timothy R Arnett
Journal: Bone Res Date: 2013-09-25 Impact factor: 13.567

Review 2. Glucocorticoid-Induced Osteoporosis.

Authors: Baruch Frenkel; Wendy White; Jan Tuckermann
Journal: Adv Exp Med Biol Date: 2015 Impact factor: 2.622

Review 3. The role of vitamin D in the endocrinology controlling calcium homeostasis.

Authors: James C Fleet
Journal: Mol Cell Endocrinol Date: 2017-04-09 Impact factor: 4.102

Review 4. Investigating Osteocytic Perilacunar/Canalicular Remodeling.

Authors: Cristal S Yee; Charles A Schurman; Carter R White; Tamara Alliston
Journal: Curr Osteoporos Rep Date: 2019-08 Impact factor: 5.096

5. Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease.

Authors: Vineet S Rolston; Anish V Patel; Thomas J Learch; Dalin Li; Dmitry Karayev; Chadwick Williams; Madhavi L Siddanthi; Stephan R Targan; Michael H Weisman; Dermot P B McGovern
Journal: J Clin Rheumatol Date: 2019-01 Impact factor: 3.517

10. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice.

Authors: Marilina Piemontese; Jinhu Xiong; Yuko Fujiwara; Jeff D Thostenson; Charles A O'Brien
Journal: Am J Physiol Endocrinol Metab Date: 2016-07-26 Impact factor: 4.310